Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158.
Xu J, Mao Y, Xu N, Bai Y, Wang D, Chen X, Yin X, Deng Y, Yang J, Zhang J, Tang J, Huang Y, Li J, Luo S, Zheng H, Zhao W, Xu M, Li N, Mao Y, Gozman A, Wu X.
Xu J, et al. Among authors: wang d.
Immunotherapy. 2024 Mar 20. doi: 10.2217/imt-2023-0294. Online ahead of print.
Immunotherapy. 2024.
PMID: 38506258